DE60039880D1 - Therapie mit lipoproteinlipase (lpl) variant - Google Patents

Therapie mit lipoproteinlipase (lpl) variant

Info

Publication number
DE60039880D1
DE60039880D1 DE60039880T DE60039880T DE60039880D1 DE 60039880 D1 DE60039880 D1 DE 60039880D1 DE 60039880 T DE60039880 T DE 60039880T DE 60039880 T DE60039880 T DE 60039880T DE 60039880 D1 DE60039880 D1 DE 60039880D1
Authority
DE
Germany
Prior art keywords
lpl
lipoproteinlipase
variant
therapie mit
therapie
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60039880T
Other languages
German (de)
English (en)
Inventor
Michael R Hayden
John J Kastelein
Katherine Julia Diane Excoffon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Amsterdam Molecular Therapeutics AMT BV
Original Assignee
University of British Columbia
Amsterdam Molecular Therapeutics AMT BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia, Amsterdam Molecular Therapeutics AMT BV filed Critical University of British Columbia
Application granted granted Critical
Publication of DE60039880D1 publication Critical patent/DE60039880D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01034—Lipoprotein lipase (3.1.1.34)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
DE60039880T 1999-06-24 2000-06-23 Therapie mit lipoproteinlipase (lpl) variant Expired - Lifetime DE60039880D1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99202048 1999-06-24
PCT/CA2000/000762 WO2001000220A2 (en) 1999-06-24 2000-06-23 Lipoprotein lipase (lpl) variant therapeutics

Publications (1)

Publication Number Publication Date
DE60039880D1 true DE60039880D1 (en) 2008-09-25

Family

ID=8240356

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60039880T Expired - Lifetime DE60039880D1 (en) 1999-06-24 2000-06-23 Therapie mit lipoproteinlipase (lpl) variant

Country Status (12)

Country Link
US (1) US20110201673A1 (https=)
EP (1) EP1200117B1 (https=)
JP (1) JP5095894B2 (https=)
AT (1) ATE404217T1 (https=)
AU (1) AU5799200A (https=)
CA (1) CA2370081C (https=)
CY (1) CY1108511T1 (https=)
DE (1) DE60039880D1 (https=)
DK (1) DK1200117T3 (https=)
ES (1) ES2311464T3 (https=)
PT (1) PT1200117E (https=)
WO (1) WO2001000220A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE437657T1 (de) * 2004-03-02 2009-08-15 Cellectar Inc Phospholipid-analoga für die behandlung von krebs
PT1761273E (pt) * 2004-06-21 2008-10-28 Amsterdam Molecular Therapeutics Bv Tratamento da esteatohepatite não alcoólica (nash)
EP2311966A3 (en) 2005-10-20 2012-09-05 Amsterdam Molecular Therapeutics (AMT) B.V. Improved AAV vectors produced in insect cells
CN103849629B (zh) 2006-06-21 2017-06-09 尤尼克尔Ip股份有限公司 具有经修饰的用于在昆虫细胞中产生aav的aav‑rep78翻译起始密码子的载体
DK2173888T3 (en) 2007-07-26 2016-11-28 Uniqure Ip Bv Baculovirus vectors comprising repeating coding sequences WITH differential preferred codons
WO2009030254A1 (en) * 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
EP2432497A1 (en) * 2009-05-18 2012-03-28 Amsterdam Molecular Therapeutics (AMT) IP B.V. Use of lipoprotein lipase (lpl) in therapy
JP6092624B2 (ja) 2009-06-12 2017-03-08 セレクター，インコーポレイティド 癌の治療並びに癌幹細胞の造影および検出のためのエーテルおよびアルキルリン脂質化合物
EP2545165B1 (en) 2010-03-11 2020-07-29 uniQure IP B.V. Mutated rep encoding sequences for use in aav production
WO2011122950A1 (en) 2010-04-01 2011-10-06 Amsterdam Molecular Therapeutics (Amt) Ip B.V. Monomeric duplex aav vectors
JP6188728B2 (ja) 2012-02-07 2017-08-30 グローバル・バイオ・セラピューティクス・インコーポレイテッドＧｌｏｂａｌ Ｂｉｏ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 核酸送達の区画化方法ならびにその組成物および使用
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CA2942289C (en) 2014-03-10 2024-05-21 Uniqure Ip B.V. Further improved aav vectors produced in insect cells
MA41035A (fr) * 2014-08-19 2017-08-15 Shire Human Genetic Therapies Lipoprotéine lipase pour le traitement d'affections liées à une hypertriglycéridémie, y compris la pancréatite aiguë
US12123030B2 (en) 2016-05-18 2024-10-22 Modernatx, Inc. Polynucleotides encoding lipoprotein lipase for the treatment of hyperlipidemia
WO2018109207A1 (en) 2016-12-16 2018-06-21 Uniqure Ip B.V. Immunoadsorption
JP7764129B2 (ja) 2017-07-10 2025-11-05 ユニキュアー アイピー ビー．ブイ． ヒトにおけるａａｖ遺伝子療法のための手段及び方法
EP3655538A1 (en) 2017-07-20 2020-05-27 uniQure IP B.V. Improved aav capsid production in insect cells
WO2019129859A1 (en) 2017-12-29 2019-07-04 Uniqure Ip B.V. Modified viral vectors and methods of making and using the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2188675A1 (en) * 1994-04-11 1995-10-19 Savio L. C. Woo Compositions and methods for gene therapy to treat disease
US5658729A (en) * 1994-10-11 1997-08-19 The University Of British Columbia Method, reagent and kit for evaluating susceptibility to premature atherosclerosis

Also Published As

Publication number Publication date
CY1108511T1 (el) 2014-04-09
EP1200117B1 (en) 2008-08-13
CA2370081C (en) 2014-06-03
PT1200117E (pt) 2008-11-26
US20110201673A1 (en) 2011-08-18
WO2001000220A3 (en) 2001-07-12
EP1200117A2 (en) 2002-05-02
DK1200117T3 (da) 2008-11-17
ATE404217T1 (de) 2008-08-15
JP5095894B2 (ja) 2012-12-12
WO2001000220A2 (en) 2001-01-04
JP2003503355A (ja) 2003-01-28
CA2370081A1 (en) 2001-01-04
ES2311464T3 (es) 2009-02-16
AU5799200A (en) 2001-01-31

Similar Documents

Publication Publication Date Title
DE60039880D1 (en) Therapie mit lipoproteinlipase (lpl) variant
EP1918300A3 (en) Peptide-based immunization therapy for treatment of atherosclerosis
EP2261349A3 (en) Neisseria meningitidis antigens and compositions
DE69636453D1 (de) Modulation der aktivität des cholesteryl-ester-transfer-proteins (cetp)
GB9916529D0 (en) Antigenic peptides
IL135687A0 (en) A novel human checkpoint kinase, hcds1, compositions and methods
GB9606040D0 (en) Active peptide
EP1037999A4 (en) POLYPEPTIDES AND NUCLEOTIDES PORPHYROMONAS GINGIVALIS
BG103472A (en) Polypeptides encoded by a human lipase-like gene, compositions and methods
ATE218064T1 (de) Immunogene tlp-zusammensetzung
ATE375390T1 (de) G-protein-gekoppelter rezeptor-ähnliche proteine
EP1462518A4 (en) GENE AND PROTEIN ASSOCIATED WITH ADIPOCYTE DIFFERENTIATION
WO2001044514A3 (en) Methods and compositions for identifying morphogenic protein analogs using morphogenic protein responsive inhibitory elements
WO2002048312A3 (en) Backbone cyclized inhibitors of heat shock proteins

Legal Events

Date Code Title Description
8364 No opposition during term of opposition